BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report. World J Clin Oncol 2021; 12(4): 272-281 [PMID: 33959480 DOI: 10.5306/wjco.v12.i4.272]
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm
Number Citing Articles
1
Young Kee Shong. Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid CancerInternational Journal of Thyroidology 2021; 14(2): 98 doi: 10.11106/ijt.2021.14.2.98
2
Tomohiro Enokida, Makoto Tahara. Management of VEGFR-Targeted TKI for Thyroid CancerCancers 2021; 13(21): 5536 doi: 10.3390/cancers13215536
3
Yao Zhang, Junge Deng, Jize Wang. Cardiovascular toxicities associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a pharmacovigilance study based on FDA adverse event reporting systemInternational Journal of Clinical Pharmacy 2025;  doi: 10.1007/s11096-025-01962-8
4
Tingting Ren, Tao Zhong, Fuhua Yang, Xuesong Liao, Mei Yang, Lingling Ji, Zonglin Guo, Jun Huang. Immune Reconstitution After Total Parathyroidectomy and Forearm Transplantation in Chronic Renal FailureJournal of Craniofacial Surgery 2024;  doi: 10.1097/SCS.0000000000010713